COVID-19 in Immunocompromised Patients : A Systematic Review
Thieme. All rights reserved..
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was first identified as a novel coronavirus in Wuhan, Hubei province, central China, in December 2019, and is responsible for the 2019-to-present pandemic. According to the most recent data released by the World Health Organization, more than 200 million people have been infected by SARS-CoV-2 so far, and more than 4 million people died worldwide. Although our knowledge on SARS-CoV-2 and COVID-19 is constantly growing, data on COVID-19 in immunocompromised patients are still limited. The aim of the present systematic review is to describe clinical picture, disease severity, proposed treatment regimen, and response to vaccination in patients with different types and severity of immunosuppression.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Seminars in respiratory and critical care medicine - 42(2021), 6 vom: 18. Dez., Seite 839-858 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stainer, Anna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 12.01.2022 Date Revised 12.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1055/s-0041-1740110 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334545145 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334545145 | ||
| 003 | DE-627 | ||
| 005 | 20231225223928.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1055/s-0041-1740110 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1115.xml |
| 035 | |a (DE-627)NLM334545145 | ||
| 035 | |a (NLM)34918325 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stainer, Anna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 in Immunocompromised Patients |b A Systematic Review |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.01.2022 | ||
| 500 | |a Date Revised 12.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Thieme. All rights reserved. | ||
| 520 | |a Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was first identified as a novel coronavirus in Wuhan, Hubei province, central China, in December 2019, and is responsible for the 2019-to-present pandemic. According to the most recent data released by the World Health Organization, more than 200 million people have been infected by SARS-CoV-2 so far, and more than 4 million people died worldwide. Although our knowledge on SARS-CoV-2 and COVID-19 is constantly growing, data on COVID-19 in immunocompromised patients are still limited. The aim of the present systematic review is to describe clinical picture, disease severity, proposed treatment regimen, and response to vaccination in patients with different types and severity of immunosuppression | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Systematic Review | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Amati, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Suigo, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Simonetta, Edoardo |e verfasserin |4 aut | |
| 700 | 1 | |a Gramegna, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Voza, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Aliberti, Stefano |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Seminars in respiratory and critical care medicine |d 1997 |g 42(2021), 6 vom: 18. Dez., Seite 839-858 |w (DE-627)NLM093752415 |x 1098-9048 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2021 |g number:6 |g day:18 |g month:12 |g pages:839-858 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/s-0041-1740110 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2021 |e 6 |b 18 |c 12 |h 839-858 | ||